Cas:213920-49-1 N,N’-BIS(METHOXYMETHYL)DIAZA-15-CROWN-5 manufacturer & supplier

Chemical Name:N,N’-BIS(METHOXYMETHYL)DIAZA-15-CROWN-5

CAS.NO:213920-49-1

Synonyms:1,4,10-Trioxa-7,13-diazoniacyclopentadecane, 7,13-bis(methoxymethyl)-;7,13-Bis(methoxymethyl)-1,4,10-trioxa-7,13-diazoniacyclopentadecane

Molecular Formula:C₁₄H₃₂N₂O₅

Molecular Weight:308.413

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:392.4±42.0 °C at 760 mmHg

Density:N/A

Index of Refraction:

PSA:

Exact Mass:308.230011

LogP:-0.44

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1,4,10-Trioxa-7,13-diazoniacyclopentadecane, 7,13-bis(methoxymethyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7,13-Bis(methoxymethyl)-1,4,10-trioxa-7,13-diazoniacyclopentadecane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4,10-Trioxa-7,13-diazoniacyclopentadecane, 7,13-bis(methoxymethyl)- Use and application,1,4,10-Trioxa-7,13-diazoniacyclopentadecane, 7,13-bis(methoxymethyl)- technical grade,usp/ep/jp grade.

Related News: From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. N,N’-BIS(METHOXYMETHYL)DIAZA-15-CROWN-5 manufacturer This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. N,N’-BIS(METHOXYMETHYL)DIAZA-15-CROWN-5 supplier From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. N,N’-BIS(METHOXYMETHYL)DIAZA-15-CROWN-5 vendor This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them. N,N’-BIS(METHOXYMETHYL)DIAZA-15-CROWN-5 factory After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.